Cargando…

CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation

Preclinical and clinical data suggest CD40 activation contributes to renal inflammation and injury. We sought to test whether upregulation of CD40 in the kidney is a causative factor of renal pathology and if reduction of renal CD40 expression, using antisense oligonucleotides (ASOs) targeting CD40,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donner, Aaron J, Yeh, Steve T, Hung, Gene, Graham, Mark J, Crooke, Rosanne M, Mullick, Adam E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014534/ https://www.ncbi.nlm.nih.gov/pubmed/26623936 http://dx.doi.org/10.1038/mtna.2015.40

Ejemplares similares

Antisense oligonucleotide–mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice
por: Bell, Thomas A., et al.
Publicado: (2021)

Antisense oligonucleotides targeting angiotensinogen: insights from animal studies
por: Wu, Chia-Hua, et al.
Publicado: (2019)

Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr(−/−) mice
por: Bell, Thomas A., et al.
Publicado: (2013)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels
por: Liang, Xue-hai, et al.
Publicado: (2017)

Effects of an Antisense Oligonucleotide Inhibitor of C‐Reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers
por: Noveck, Robert, et al.
Publicado: (2014)

Effects of Antisense Oligonucleotides against C-Reactive Protein on the Development of Atherosclerosis in WHHL Rabbits
por: Yu, Qi, et al.
Publicado: (2014)

Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
por: Prakash, Thazha P, et al.
Publicado: (2019)

Defining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides
por: Lima, Walt F., et al.
Publicado: (2014)

Antisense technology: A review
por: Crooke, Stanley T., et al.
Publicado: (2021)

Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2016)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2018)

Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
por: Bailey, Jeffrey K., et al.
Publicado: (2017)

Intracerebral Infusion of Antisense Oligonucleotides Into Prion-infected Mice
por: Nazor Friberg, Karah, et al.
Publicado: (2012)

Antisense Technology: An Emerging Platform for Cardiovascular Disease Therapeutics
por: Lee, Richard G., et al.
Publicado: (2013)

Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
por: Scoles, Daniel R., et al.
Publicado: (2017)

COPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of oligonucleotides from endocytic pathways
por: Liang, Xue-hai, et al.
Publicado: (2018)

Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy
por: Grote Beverborg, Niels, et al.
Publicado: (2021)

The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA
por: Vickers, Timothy A., et al.
Publicado: (2015)

mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway
por: Liang, Xue-hai, et al.
Publicado: (2019)

Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
por: Schmidt, Karsten, et al.
Publicado: (2017)

RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery
por: Lima, Walt F., et al.
Publicado: (2016)

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro(®)): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
por: Geary, Richard S., et al.
Publicado: (2015)

Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs
por: Liang, Xue-Hai, et al.
Publicado: (2018)

Targeting of Repeated Sequences Unique to a Gene Results in Significant Increases in Antisense Oligonucleotide Potency
por: Vickers, Timothy A., et al.
Publicado: (2014)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2017)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus
por: Liang, Xue-Hai, et al.
Publicado: (2017)

Antisense Oligonucleotides Capable of Promoting Specific Target mRNA Reduction via Competing RNase H1-Dependent and Independent Mechanisms
por: Vickers, Timothy A., et al.
Publicado: (2014)

Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models
por: Moore, Lauren R., et al.
Publicado: (2017)

Antisense Oligonucleotide Induction of Progerin in Human Myogenic Cells
por: Luo, Yue-Bei, et al.
Publicado: (2014)

Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver
por: Miller, Colton M., et al.
Publicado: (2016)

Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides
por: Aung-Htut, May T., et al.
Publicado: (2019)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023)

In-silico study of antisense oligonucleotide antibiotics
por: Chen, Erica S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ule3p1ue0o3k3197snvmarphf4